NeuroDerm (NDRM)

[John-Knee]

Research analysts at Jefferies Group assumed coverage on shares of Neuroderm (NASDAQ:NDRM) in a report released on Thursday. The firm set a “buy” rating and a $21.00 price target on the stock. Jefferies Group’s price objective points to a potential upside of 57.30% from the stock’s previous close.

Neuroderm (NASDAQ:NDRM) opened at 13.35 on Thursday. Neuroderm has a 52-week low of $5.67 and a 52-week high of $19.07. The stock’s 50-day moving average is $13. and its 200-day moving average is $11.. The company’s market cap is $226.90 million.

Neuroderm (NASDAQ:NDRM) last issued its quarterly earnings data on Thursday, April 2nd. The company reported ($2.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $2.20. On average, analysts predict that Neuroderm will post $-1.52 earnings per share for the current fiscal year.

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (NASDAQ:NDRM) disorders. It develops product candidates for the treatment of Parkinson’s disease and cognition.